Regulated information

Buyback programs - May 2024

Monthly communication regarding buyback programs 
 

Monthly information regarding the total number of voting rights – May 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthy information regarding the total number of voting rights and shares making of the share capital - April 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Buyback programs - April 2024

Monthly communication regarding buyback programs

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

Monthly information regarding the total number of voting rights – March 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

Monthly information regarding the total number of voting rights – February 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthly information regarding the total number of voting rights – January 2024

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

Monthly information regarding the total number of voting rights – December 2023

As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

Monthly information regarding the total number of voting rights and shares making of the share capital - September 2023

As per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthly information regarding the total number of voting rights and shares making of the share capital - August 2023

As per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

Monthly information regarding the total number of voting rights - July 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

Monthly information regarding the total number of voting rights - April 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

Monthly information regarding the total number of voting rights - May 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

Monthly information regarding the total number of voting rights - June 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

Monthly information regarding the total number of voting rights - March 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

Monthly information regarding the total number of voting rights - February 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the « Reglement Général de L’Autorité des Marchés Financiers »

Monthly information regarding the total number of voting rights - January 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

Monthly information regarding the total number of voting rights - december 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthly information regarding the total number of voting rights ans shares making of the share capital - november

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthly communication regarding buyback programs - october 2022

First nine months 2022 sales: €405M

In line with year-end outlook

Monthly communication regarding buyback programs - September 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

2022 HALF YEAR RESULTS Additional information on the Group’s strategy

Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook.

2022 HALF YEAR RESULTS

Sales: €271m (up 6.0% as reported)
Essentials sales: €154m (up 9.8% as reported)
EBIT before depreciation of acquired assets: €52m (19.0% of sales)
Net income - Group share: €21m (7.9% of sales)
EBITDA: €62m (22.9% of sales)

Monthly information regarding the total number of voting rights and shares making of the share capital - August 2022

As per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthly information regarding the total number of voting rights and shares making of the share capital - July 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

H1 2022 Sales

H1 2022 Sales: €271m, up 6.1%
+2.0% on a like-for-like basis
H1 2022 Essentials Sales: €154m, up 9.8%
+6.8% on a like-for-like basis

Monthly information regarding the total number of voting rights and shares making of the share capital - june 2022

as per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthly information regarding the total number of voting rights and shares making of the share capital - may 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthly information regarding the total number of voting rights and shares making of the share capital - april 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

Availability of the 2021 universal registration document

Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022.

Q1 2022 SALES: €135M

Q1 2022 SALES: €135M
(UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES)
Q1 2022 ESSENTIALS SALES: €77M
(UP 8.1% AS REPORTED, UP 5.5 AT CONSTANT EXCHANGE RATES)

Monthly information regarding the total number of voting rights and shares - march 2022

Monthly information regarding the total number of voting rights and shares making of the share capital

as per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

2021 Annual results

ALL FINANCIAL INDICATORS UP.
Annual sales: €521m (up 21.9% as reported).
Essentials sales: €296m (up 34.0% as reported).
EBIT before depreciation of acquired assets: €101m (up 54.5%).
Net income - Group share: €63m (up 226.9%).

Monthly information regarding the total number of voting rights and shares making of the share capital- february 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Double-digit growth in 2021

Total Group Sales: €521 million (up 21.9% as reported)
Annual Sale of Essential products: €296 million (up 34.0% as reported)

Clone of Monthly information regarding the total number of voting rights and shares making of the share capital

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Monthly information regarding the total number of voting rights and shares making of the share capital

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Bilan annuel des moyens alloués au contrat de liquidité (décembre 2021)

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2021

Monthly information regarding the total number of voting rights and shares making of the share capital - November 2021

As per article 223.16 of the « Règlement Général de l’Autorité des marchés financiers »

Monthly information regarding the total number of voting rights and shares making of the share capital - October 2021

Third quarter revenues: €132 million

Monthly information regarding the total number of voting rights and shares making of the share capital - September 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Monthly information regarding the total number of voting rights and shares making of the share capital - July 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Monthly information regarding the total number of voting rights and shares making of the share capital - July 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

2021 first half results

2021 Half year results

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2020

Monthly information regarding the total number of voting rights and shares making of the share capital - June 2021

Monthly information regarding the total number of voting rights and shares making of the share capital - April 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Monthly information regarding the total number of voting rights and shares making of the share capital - April 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

Q1 2021 sales

Monthly information regarding the total number of voting rights and shares making of the share capital - March 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

Monthly information regarding the total number of voting rights and shares making of the share capital - February 2021

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Vetoquinol wins the Animal Pharm’s award for best European company 2020

February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm.

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

Monthly information regarding the total number of voting rights and shares making of the share capital - January 2021

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.”

Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia

January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health.

Monthly information regarding the total number of voting rights and shares making of the share capital - December 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2020

Monthly information regarding the total number of voting rights and shares making of the share capital - November 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Monthly information regarding the total number of voting rights and shares making of the share capital - October2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Q3 2020 sales: €114.5 million* (Up 14.3%)

Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year.

Monthly information regarding the total number of voting rights and shares making of the share capital -September 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

VETOQUINOL, SNGTV and FARMVETSYSTEMS sign a partnership agreement to offer a common, innovative digital solution to the veterinary healthcare market. September 28th, 2020 (Paris, France) VETOQUINOL, FARMVET SYSTEMS and SNGTV have signed a partnership agreement aimed at offering a common solution highlighting the complementarity of their two software, VetIMPRESS and Vetélevage to farm vets. Aware of their shared philosophy aimed at optimizing vets actions thanks to new digital technologies, they are pooling these two software programs to strengthen the role of farm vets in animal health and welfare.

Vetimpress delivering digital solutions to farm vets with a growing network of partnerships

September 21st, 2020 (Northern Ireland) – VetIMPRESS the secure data management platform has recently implemented a series of integrations, reinforcing its position as a leading source of information for farm animal vets. The platform has grown its connections to over 100 external sources across 10 countries. The partnerships are set to improve connectivity across the industry, providing a single source of truth to better inform ethical, safe and productive veterinary decisions.
 

Monthly information regarding the total number of voting rights and shares making of the share capital -Aout 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Vetoquinol finalizes the acquisition of Profender® and Drontal® product families

September 1st, 2020 (Lure, France) – Vetoquinol confirms the completion of the acquisition of Profender® and Drontal® product families for the European Economic Area and the UK. This acquisition is effective from August 1st, 2020.

Monthly information regarding the total number of voting rights and shares making of the share capital -July 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales)

At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

Monthly information regarding the total number of voting rights and shares making of the share capital -June 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 30 juin 2020

Vetoquinol is moving forward with the acquisition of Profender® and Drontal® and related pipeline assets following communication from the European commission

June 9th, 2020 (Lure, France) - The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division by Elanco Animal Health.

Monthly information regarding the total number of voting rights and shares making of the share capital -May 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Monthly information regarding the total number of voting rights and shares making of the share capital - April 2020

Dominique Derveaux appointed Group Chief Operations Officer Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin.

Availability of the 2019 universal registration document

Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020.

Q1 2020 sales €103.4 million (Up 13.7%)

Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates.

Monthly information regarding the total number of voting rights and shares making of the share capital - MArch 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales)

At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

Covid-19: Vetoquinol donates masks to neighboring healthcare facilities

Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions.

Monthly information regarding the total number of voting rights and shares making of the share capital - February 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK

February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health.

Monthly information regarding the total number of voting rights and shares making of the share capital - January 2020

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

2019 sales: €396.0 million (Up 7.6%)

The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates.

Bilan semestriel des moyens alloués au contrat de liquidité - french

Au titre du contrat de liquidité confié par la Société VETOQUINOL à la Société ODDO CORPORATE FINANCE, les moyens suivants figuraient au compte de liquidité au 31 décembre 2019

Monthly information regarding the total number of voting rights and shares making of the share capital - December 2019